Dental and medical products company Henry Schein (NASDAQ:HSIC) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 6.3% year on year to $3.37 billion. Its non-GAAP profit of $1.32 per share was 8.4% above analysts’ consensus estimates.
Is now the time to buy HSIC? Find out in our full research report (it’s free for active Edge members).
Henry Schein (HSIC) Q1 CY2026 Highlights:
- Revenue: $3.37 billion vs analyst estimates of $3.34 billion (6.3% year-on-year growth, 0.8% beat)
- Adjusted EPS: $1.32 vs analyst estimates of $1.22 (8.4% beat)
- Adjusted EBITDA: $289 million vs analyst estimates of $275.1 million (8.6% margin, 5.1% beat)
- Management reiterated its full-year Adjusted EPS guidance of $5.30 at the midpoint
- Operating Margin: 5.4%, in line with the same quarter last year
- Organic Revenue rose 2.5% year on year (miss)
- Market Capitalization: $8.53 billion
StockStory’s Take
Henry Schein’s first quarter results were well received by the market, with outperformance driven by robust gains in U.S. dental and global technology segments. CEO Frederick Lowery pointed to ongoing market share gains and stable dental procedure volumes as key contributors, while highlighting that merchandise price increases and continued investments from dental service organizations (DSOs) underpinned growth. The medical business was impacted by a lighter flu season, which weighed on demand for point-of-care diagnostic products, but this was offset by solid growth in Home Solutions and technology-driven offerings.
Looking ahead, management’s guidance reflects confidence in stable dental and medical end markets, as well as the ongoing benefits expected from value creation initiatives. Lowery emphasized the company’s focus on technology adoption, operational streamlining, and a shift toward higher-margin products, stating, “We are committed to achieving greater than $200 million in annual operating income improvement in the next few years.” CFO Ronald South highlighted that the largest improvements from cost savings and gross profit optimization are expected in the second half of the year, with digital solutions and proprietary brands positioned as future growth engines.
Key Insights from Management’s Remarks
Management highlighted that sales momentum in dental and technology, alongside gross margin expansion, drove quarterly performance. Ongoing cost and value initiatives are expected to support margins and future profitability.
- Dental market share gains: Henry Schein attributed its strong quarter to continued market share expansion with both independent practices and DSOs. CEO Frederick Lowery noted that DSOs are growing faster than the broader market, with Henry Schein’s national relationships fueling volume growth in dental merchandise and equipment.
- Technology solutions drive growth: The company’s cloud-based practice management platforms, including Dentrix Ascend and Dentally, experienced a 25% year-over-year increase in subscribers. Management cited the launch of an AI-powered clinical workflow as a key milestone, with demand for digital solutions remaining robust among dental professionals.
- Value and specialty product momentum: Sales of value implant systems grew at a high single-digit rate, outpacing premium implants. The acquisition of a controlling interest in S.I.N. 360 strengthens Henry Schein’s position in the U.S. value implant market, supporting integration and growth initiatives.
- Gross margin expansion: Gross margin improved due to favorable business mix, increased contribution from proprietary brands, and early benefits from dynamic pricing initiatives. South noted that proprietary brands deliver higher margins, and strategic pricing actions have become more responsive to market changes.
- Medical business mixed: While nonacute care and Home Solutions businesses continued to perform well, a light flu season led to lower demand for point-of-care diagnostics. Excluding this segment, underlying medical sales growth would have been mid-single digits, according to management.
Drivers of Future Performance
Henry Schein expects technology adoption, proprietary brands, and operational improvements to underpin growth and margin expansion in the coming quarters.
- Operational excellence focus: Management is prioritizing a continuous improvement mindset, aiming to streamline processes and enhance agility. Lowery outlined ongoing initiatives to centralize back-office functions and optimize procurement, which are expected to yield $125 million in run-rate operating income benefits by year-end, with further improvements over the next several years.
- Digital and AI strategy: The company is investing in AI-enabled software and expanding its global e-commerce platform. These digital initiatives are intended to improve practice productivity for customers and support higher-margin, recurring revenue streams, helping Henry Schein differentiate itself in a competitive landscape.
- Macro and cost risks: Management noted that higher oil prices and potential tariff changes could pressure margins through increased freight and product costs. However, South explained that mitigation strategies, including selective price adjustments and cost controls, are designed to limit the impact on profitability unless there is a significant, sustained spike in oil prices.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will watch (1) the pace of adoption for AI-powered and cloud-based dental software, (2) the progression of cost savings and value creation initiatives—especially as benefits are weighted to the second half, and (3) the recovery in medical segment sales, particularly outside point-of-care diagnostics. Execution in proprietary brands and digital offerings will also be key for tracking sustained margin gains.
Henry Schein currently trades at $75.74, up from $72.02 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.